Evocra home

News

Arcadis signs exclusive agreement with Evocra

Posted

Categories

Arcadis signs exclusive agreement with Evocra to gain global license for innovative PFAS treatment technology

Amsterdam, 22 October, 2019 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced it has signed a Heads of Agreement with EVOCRA, enabling an exclusive commercial negotiating period within which the parties will finalize a license agreement for sole rights to the EVOCRA technology for PFAS solutions. This technology, which has already been proven at commercial scale on two projects in Australia, will be a welcome addition to Arcadis’ existing suite of PFAS solutions, allowing Arcadis to continue to offer a differentiated solution for clients globally.

PFAS, or per- and poly-fluorinated alkyl substances, were incorporated in commercial, industrial and consumer products, including textile coatings, stain repellents, electronics and mist suppressants. PFAS were also components of firefighting foams known as Aqueous Film Forming Foam (AFFF).

In recent years, under increasing scientific and regulatory scrutiny and community awareness, more is being understood about PFAS toxicity, environmental persistence, aquifer mobility and the potential for this emerging contaminant to bioaccumulate in natural environments and enter the food chain.

EVOCRA, an Australian-based water treatment company, have a patented technology that uses ozone fractionation to separate and concentrate PFAS from impacted media. Their process has been demonstrated at commercial scale as having the ability to remove PFAS and deliver an output that meets the most stringent discharge requirements set by regulators and other relevant authorities.

Arcadis is at the forefront of a global effort to remove PFAS from impacted sites and environments, with over 75 projects in their portfolio, representing over 300 individual sites in 12 countries. This deal will continue Arcadis’ push to achieve greater market share within the PFAS space and provide their clients with a unique and innovative solution that can be used on its own and/or in conjunction with other technologies to remove PFAS from impacted sources.

Peter Oosterveer, CEO, Arcadis: “EVOCRA and their treatment process provides our clients with an innovative solution to cost-effectively remove a complex contaminant from their assets and improve our environment. When the EVOCRA technology is coupled with either Arcadis developed or other commercially available destructive technologies, we will have the ability to offer our clients a zero-waste outcome.”

The Ozone fractionation used by EVOCRA has benefits over other separation and/or adsorption technologies, especially for liquids that have high concentrations of PFAS and for complex waste streams with multiple contaminants.

For Arcadis enquiries regarding the agreement please contact:

ARCADIS CORPORATE COMMUNICATIONS 
Jochem Binst 
Mobile: +32 471202679 
E-mail: jochem.binst@arcadis.com

ARCADIS INVESTOR RELATIONS 
Jurgen Pullens 
Mobile: +31 6 51599483 
E-mail: jurgen.pullens@arcadis.com

For matters related to Evocra's capabilities please contact us here.